All are true regarding treatment of Guillain-Barre syndrome EXCEPT:
**Core Concept**
Guillain-Barre syndrome (GBS) is an autoimmune disorder characterized by the immune system's attack on the peripheral nervous system, leading to muscle weakness, paralysis, and autonomic dysfunction. The primary goal of treatment is to reduce the severity of symptoms and prevent long-term complications.
**Why the Correct Answer is Right**
Treatment of GBS involves the administration of intravenous immunoglobulin (IVIG) to modulate the immune response and reduce inflammation. This is based on the understanding that GBS is an autoimmune disorder, and IVIG has been shown to be effective in reducing the severity and duration of symptoms. The pathophysiology of GBS involves the activation of immune cells, such as T cells and B cells, which produce antibodies against the myelin sheath of peripheral nerves, leading to demyelination and nerve conduction block.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because plasma exchange is not the primary treatment for GBS. While plasma exchange may be used in some patients, the evidence for its effectiveness is less robust compared to IVIG.
**Option B:** This option is incorrect because corticosteroids are not the first-line treatment for GBS. Corticosteroids may be used in some cases, but they are not as effective as IVIG in reducing the severity and duration of symptoms.
**Option C:** This option is incorrect because it is not a true statement regarding the treatment of GBS. The correct treatment involves IVIG and, in some cases, plasma exchange.
**Clinical Pearl / High-Yield Fact**
One important point to remember is that early treatment with IVIG within the first two weeks of symptom onset is associated with improved outcomes and reduced long-term disability.
**Correct Answer: A. Plasma exchange is not the primary treatment for Guillain-Barre syndrome.**